Dr. Edward J. Benz, Jr., talked about research to develop treatments for cancer that are more efficient and less toxic, by specifically targeting tumors using genetic analysis.
Tags: BasicResearch, TargetedTherapy
Cigall Kodach, PhD, spoke about the problems in today’s biology and medicine research on a panel at the Forbes Under 30 Summit.
Dana-Farber patient Grace Silva served as a case study of an “exceptional responder” for a treatment she underwent at the recommendation of her oncologists, Dr. Jochen Lorch and Dr. Nikhil Wagle.
Dr. Toni Choueiri led a study that found patients with non–clear cell renal cell carcinoma, PD-L1 positivity is associated with worse clinical outcomes, including a shorter overall survival and time to recurrence.
Dr. William Kaelin commented on the cancer-stem-cell model, and the possibility of controlling cancer without killing it.
Rafael Irizarry, PhD, co-led a new study investigating all stages and types of cancers that appear to share a telltale signature of widespread changes to the epigenome.
Tags: BasicResearch, Genomics
John Quackenbush, PhD, commented on a study that showed understanding a tumor's genomic profile is more likely to lead to an effective treatment.
Dr. Koen M. A. Dreijerink participated in a study that suggested the MEN1 mutation is also involved in the formation of breast cancer tumors.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: